Despite some periodic drops, the overall sentiment toward
Amgen (AMGN) seems bullish. Many investment services, including
Caisse Des Depots ET Consignations and
American Century Companies Inc, have adjusted their stock positions in Amgen. Significant attention remains drawn to their ongoing operations, evidenced by the observation that it is outperforming the healthcare sector. With just over a 2.9% rise since their last earnings report, Amgen's performance appears strong, and their stock appears to be a good value for long-term investment. Several other companies, including
Modern Wealth Management LLC,
Zions Bancorporation N.A., and others have grown their holdings in Amgen. The
Vanguard Group Inc. holds a significant stake in Amgen, amounting to $13.74 billion. Notably, the company recently declared a US$2 dividend per share for Q2 2025, which adds to investor optimism. Notably, they are involved in potentially successful research, such as the ROCATINLIMAB PHASE 3 IGNITE STUDY for moderate to severe atopic dermatitis.
Amgen AMGN News Analytics from Tue, 26 Nov 2024 08:00:00 GMT to Sat, 29 Mar 2025 11:27:45 GMT -
Rating 7
- Innovation 5
- Information 8
- Rumor 2
